Taking the Static Out of Drug Marketing
Executive Summary
Launching a new drug involves a complex series of decision points in multiple areas including clinical trial design, target markets, marketing mix and regulatory/reimbursement issues. The traditional marketing approach tailors strategies to specific physician and patient segments in a linear manner that can be slow in responding to unanticipated results. McKinsey has developed what it calls Dynamic Pharmaceutical Product Marketing, which is a framework that incorporates systems thinking with traditional marketing's best practices to help product companies deal more efficiently and effectively with the variables of the marketplace.
You may also be interested in...
Despite 'Remarkable' ROI On Women’s Health Investments, Money Still Lacking
Recent US government initiatives and growing investor interest are important for developing female-specific therapeutics, but funding is not yet where it should be.
China VBP, Localization And Other Strategies - How Far And Which Way?
Could health sector players encounter issues similar to those facing Tesla in China, a country which virtually saved the electric vehicle maker but where it is now facing challenges? Are there any lessons to be learned from a success story under China's volume-based procurement scheme? A partner at EY looks at these and other issues in an interview with Scrip.
Ratio Therapeutics On BMS Investment, Radiopharma R&D Trends, AI Use
The CEO and CSO of radiopharmaceutical company Ratio Therapeutics, which now has Bristol Myers Squibb as an investor, talk about Ratio’s R&D platforms, use of AI, an independent FAP-targeted asset and trends in radiopharma research such as combining other modalities like ADCs, in this podcast interview with Scrip